Trevi Therapeutics’ (TRVI) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a report released on Wednesday,Benzinga reports. The brokerage currently has a $21.00 price target on the stock.

A number of other brokerages have also commented on TRVI. HC Wainwright upped their target price on Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a research note on Thursday, December 12th. B. Riley reiterated a “buy” rating and set a $6.00 price objective on shares of Trevi Therapeutics in a research note on Monday, October 7th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $8.00 price objective on shares of Trevi Therapeutics in a research note on Thursday, December 12th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $9.31.

Trevi Therapeutics Trading Down 1.0 %

TRVI opened at $4.03 on Wednesday. Trevi Therapeutics has a 1-year low of $1.27 and a 1-year high of $4.68. The stock has a market capitalization of $309.77 million, a price-to-earnings ratio of -9.16 and a beta of 0.87. The business has a 50 day moving average of $3.37 and a 200-day moving average of $3.13.

Trevi Therapeutics (NASDAQ:TRVI) last issued its earnings results on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same quarter last year, the business posted ($0.08) earnings per share. Equities analysts predict that Trevi Therapeutics will post -0.49 EPS for the current year.

Hedge Funds Weigh In On Trevi Therapeutics

Several hedge funds have recently added to or reduced their stakes in TRVI. BNP Paribas Financial Markets boosted its holdings in Trevi Therapeutics by 130.9% during the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after buying an additional 6,764 shares during the last quarter. Intech Investment Management LLC bought a new position in Trevi Therapeutics during the third quarter worth about $63,000. Hsbc Holdings PLC bought a new position in Trevi Therapeutics during the second quarter worth about $61,000. SG Americas Securities LLC bought a new position in Trevi Therapeutics during the third quarter worth about $78,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in Trevi Therapeutics by 87.6% during the second quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after buying an additional 11,450 shares during the last quarter. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.